19 May 2017

Photo of the week: 2017 AMREP BMedSc(Hons) information night

2016 Central Clinical School's Bachelor of Medical Science (Honours) information evening. Drs Daphne Vogiagis and Geraldine Ooi are talking with Mr James Lee and a potential student at the Department of Surgery table. Both AMREP* schools are running the information night this year:

Thursday 13 July, 2017 6.00pm to 8.00pm

AMREP Education Centre (see map)
80 Commercial Road, Melbourne, 3004.
The AMREP schools (Central Clinical School and School of Public Health and Preventive Medicine) will showcase their research expertise and what they can offer to a BMedSc(Hons) candidate. You can meet and discuss research projects with potential supervisors after the main presentation. Refreshments will be provided.
To RSVP, please register your attendance.
See more: CCS and SPHPM BMedSc(Hons) programs
*AMREP: Alfred Medical Research and Education Precinct
 

What's on at CCS 22-26 May 2017

Paul Gill is presenting on how bacterial
DNA can protect airways in allergic
inflammation, Thu 25 May 2017
Central Clinical School (CCS) has regular seminar series and postgraduate presentations. Event notices are posted on the CCS Events calendar.

CCS staff & students can see details of both public and local events (including professional development courses, trade fairs and Graduate Research Student calendars) and deadlines, at the CCS intranet's Announcements page. Various departments have their own calendars.

Save the date

Thu 13/07/2017 AMREP Bachelor of Medical Science (Honours) information evening
Mon 31/07/2017 Translational Research symposium: RSVP

CCS Publications update: 13-19 May 2017

Professor Andrew Spencer is
last author on two papers this
week on multiple myeloma
Recent publications for Central Clinical School affiliated authors in the departments of Australian Centre for Blood Diseases (ACBD), Anaesthesia, Diabetes, Gastroenterology, Immunology, Infectious Diseases, Melbourne Sexual Health Centre (MSHC), Monash Alfred Psychiatry research centre (MAPrc) and Surgery.  

When beauty is not in the eye of the beholder

Your brain distorts your perception
of yourself in BDD.
by Anne Crawford

Body Dysmorphic Disorder (BDD) is a condition in which the individual is preoccupied or excessively concerned by what they see as flaws in their appearance, whether it’s the size or shape of their nose, the symmetry of their cheekbones or an imaginary defect elsewhere on their body.

17 May 2017

International trauma program to reduce burden of injury

Saudi Arabia records over half a million road accidents each year.
Video image
The Kingdom of Saudi Arabia records approximately 526,000 road accidents per annum - 7,900 people die each year due to road trauma and over 40,000 people are injured every year. The death rate from road accidents, per head of population, is five times higher than in Australia. This significant burden of injury endured by the Saudi people has been recognised by the Kingdom of Saudia Arabia as preventable.

Internationally, trauma is the leading cause of death in the first four decades of life and the second most frequent cause of deaths in all age groups. This has prompted the World Health Organisation (WHO) to declare the ‘Decade of Action’ (2011-2020) on road safety.

Monash findings raise hopes for better stroke treatment

Dr Be'eri Niego (right) with honours
student Mr Felix Lee in 
Prof Rob Medcalf's lab.
by Anne Crawford

Around the world, the race is on to find new ways to treat ischaemic (blood clot-derived) stroke. Some of these efforts are aimed at increasing the safety of the main treatment currently in use, the clot-busting enzyme tissue-type Plasminogen Activator (t-PA). t-PA is effective in improving recovery if administered quickly – within 4.5 hours of a stroke. But as it dissolves the clots that cause stroke, t-PA also weakens the blood vessels in the brain that form what’s called the blood-brain barrier (BBB), increasing the risk of bleeding in the brain, potentially lethally, which limits the therapy’s use.

16 May 2017

Translational Research Symposium Speaker Spotlight: Professor Kathryn North

Professor Kathryn North AM
Monash University's 3rd annual Translational Research Symposium is being hosted by its three metropolitan clinical schools on 31 July 2017. The symposium will host a diverse group of medical researchers presenting their work into translational research. RSVP here.

The Keynote speaker for the event is Professor Kathryn North AM, Director of the Murdoch Children's Research Institute, Director of the Victorian Clinical Genetics Service and the David Danks Professor of Child Health Research at the University of Melbourne.

Call for participants in the Translational Research Young Investigator poster competition

The TR Symposium is coming up soon!
The 3rd annual Monash University Translational Research (TR) Symposium will be held 31 July 2017. The event is hosted by the three Monash clinical schools and will showcase the diverse research from these schools.

A Young Investigator poster competition will be held, with a winning prize of $500. The competition is open to graduate student and early career researchers, who are within 5 years of completing their PhD. Entries now invited.

Congratulations to Professor Paul Myles on winning Clinial Trial of the Year!

Professor Paul Myles with Minister Greg Hunt MP at the award
ceremony, Friday 19 May 2017. Photo: Sophie Wallace
Professor Paul Myles (pictured) has won Clinical Trial of the Year, awarded by the Australian Clinical Trials Alliance.  The award was presented by the Federal Health Minister, the Hon Greg Hunt MP, on Friday 19 May 2017.

Professor Myles is the head of the Department of Anaesthesia and Perioperative Medicine at Monash and Alfred. He has led a number of large studies involving many centres and thousands of patients to investigate the safety of the anaesthetic drug nitrous oxide, whether patients taking aspirin can safely continue up to and post-surgery, and the safety of an anti-bleeding drug called tranexamic acid (TXA). Results of these international multi-centre trials run across several countries have been published in the prestigious journals The New England Journal of Medicine (NEJM) (2016 and 2017) and The Lancet (2014).

The trial for which Professor Myles received the ACTA award is Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) – results for which were published in NEJM last year.

The ATACAS team collaborated internationally with 30 hospitals across seven countries with over 4,600 patients participating. The results show that TXA could almost halve the number of people who suffer complications with bleeding following open heart and other major surgery.

“The results were very clear-cut and reassuring,” said Professor Myles. “TXA does not increase thrombosis after open heart surgery. Furthermore, there was strong evidence that TXA nearly halved the risk of serious bleeding complications – meaning less bleeding, fewer blood transfusions and far less need for emergency re-operation following surgery.

“The findings mean that almost every heart surgery patient can now be treated with TXA, and that we can safely use a higher dose than previously. Use of TXA can also be safely expanded to prevent bleeding with other kinds of major surgery, such as knee and hip replacements, trauma surgery and spinal surgery, operations where TXA is not much used at present.”

Currently, each year about 15,000 Australians who have heart surgery (40 per cent of the total) need blood transfusions, and up to 1000 need a second, emergency surgery. “Routine use of TXA can halve both those figures,” Professor Myles said.

The ACTA award recognises the importance of the research and its direct influence on improving patient outcomes globally.

Congratulations to Dr Shiva Akbarzadeh for Technologist Award!

Congratulations to Dr Shiva Akbarzadeh (seen here on the left with ISCT president Catherine Bollard), who won the Technologist Award for her presentation titled "CEA as an Adjunct Treatment for Major Burns: A Phase I Study".

This talk was given at the International Society for Cellular Therapy, Annual meeting London 2017. Shiva described a Phase I clinical trial outcomes on Cultured epidermal sheet autografts (CEA) on a fibrin carrier that was carried out at the Alfred 2013-2016.

15 May 2017

Congratulations to our newly completed PhD students!

Natalia Contreras Hannah Pearce Ioanna Savvidou Chu Kion Yao










Congratulations to our recently completed PhD students Natalia Contreras, Hannah Pearce, Ioanna Savvidou and Chu Kion (CK) Yao! Good luck in the next stage of the career pathway!

Congratulations to Immunology prize winners!

Heidi Fettke won the Nairn prize for top
Honours student in 2016
Congratulations to the Immunology and Human Pathology students who were recently awarded prizes for their 2016 efforts!
 

Nairn Prize: top Honours student

The Nairn Prize in Immunology, named after the Department's founding chairman, Professor Richard Nairn, is given to the top Immunology Honours student completing his or her project at Monash and coordinated within the Department of Immunology and Pathology.

New peanut allergy treatment now in clinical trials

L-R: Dr Sara Prickett, Professor Robyn O’Hehir
and Emeritus Professor Jenny Rolland have
hworked together for years on the peanut allergy
research and are co-founders of Aravax P/L.
A new peanut allergy treatment developed by Monash researchers is now beginning clinical trials in Melbourne and Adelaide. If you would like to participate, see contact details at: www.aravax.com.au/product-development.html

Professor Robyn O’Hehir is Professor/Director of the Department of Allergy, Immunology and Respiratory Medicine at Alfred Health and Monash University. Her research team, co-led by Professor Jennifer Rolland, over several years identified the critical components of the peanut allergy therapy now being developed by Aravax, an Australian spinout biotechnology company.
Related Posts Plugin for WordPress, Blogger...